Finasteride and its effects on hair loss, with discussions on the role of estradiol and estrogen. Users debate whether increased estrogen from DHT blockers contributes to hair regrowth, with concerns about potential side effects like chemical castration.
Switching from finasteride to dutasteride can worsen hair loss for some men due to increased testosterone levels. Topical treatments like RU58841 and Pyrilutamide are suggested to counteract these effects, but individual responses vary.
Pyrilutamide is being discussed as a potential hair loss treatment, but opinions are mixed, with some users skeptical about its effectiveness and the company's credibility. Some users report combining pyrilutamide with other treatments like dutasteride and microneedling, noting improvements, while others remain doubtful.
The user experienced significant hair regrowth using dutasteride (0.5 mg three times a week) and RU58841 (5% once a day), with no side effects reported from RU58841. They are considering increasing the RU58841 dose or adding minoxidil for further improvement.
Kintor is testing Pyrilutamide with Minoxidil for hair loss. Users are skeptical about its effectiveness and concerned about limited treatment options if this fails.
Hair loss is linked to DHT, with treatments like finasteride and minoxidil being common but not definitive. Economic interests influence research, and there is potential for new treatments like PP405 and RU58841.
RU58841 is a strong non-steroidal antiandrogen for hair loss but may cause cardiovascular issues in some users. Alternatives like Pyrilutamide and Breezula are suggested due to better safety profiles and lower systemic risks.
Poor diet and lifestyle contribute to male pattern baldness. Treatments like Minoxidil, dietary changes, and lifestyle adjustments may help slow hair loss.
A user increased their dutasteride dosage from 0.5mg to 1mg daily, resulting in a rise in DHT levels from 148 pg/mL to 281 pg/mL, and is considering switching back to finasteride due to continued hair loss. Replies suggest retesting and emphasize the importance of bloodwork before starting treatments.
The conversation discusses the delay in the release of GT20029 for hair loss treatment and skepticism about its effectiveness. Participants mention other treatments like verteporfin and advancements in transplant procedures as more realistic options.
Hair loss treatments still rely heavily on minoxidil, finasteride, and RU58841, with little innovation. Future treatments like stem cell therapy and RNA technology show promise but are not yet available.
The conversation discusses using estradiol mesotherapy to replicate hormone replacement therapy results while minimizing systemic exposure. It also covers the use of Spironolactone cream, which reportedly has no systemic side effects, and the potential risks of using bicalutamide and Spironolactone in men.
Hair loss treatment should target dermal white adipose tissue (DWAT) to restore hair follicles. Potential remedies include tocopherol (vitamin E), botox, rosiglitazone, niacin, kojyl cinnamate esters, and ADP355.
A user shared their experience of using finasteride for hair loss from ages 29 to 37, stopping due to side effects like low libido, and later starting testosterone therapy, which improved their well-being. The discussion includes various opinions on the effects of finasteride and testosterone on hair loss, libido, and overall health, with some users questioning the correlation between finasteride and low testosterone.
KX826 is considered a legitimate option for those who cannot use finasteride or dutasteride, but many users report it as ineffective compared to RU58841. RU58841 is favored by some due to anecdotal evidence of effectiveness, despite the lack of published clinical data.
The conversation discusses the ineffectiveness of dutasteride in halting hair loss for the user and explores the potential of PP405, which works through a different mechanism. Suggestions include considering a biopsy to determine the cause of hair loss and exploring other treatments like RU58841.
A peptide-based delivery system for finasteride shows promise in reducing systemic side effects while maintaining hair growth effectiveness. Combining this with other treatments like minoxidil and RU58841 could enhance results with lower systemic absorption.
Switching from finasteride to dutasteride can cause initial shedding, but many see long-term hair regrowth and stabilization. Responses vary, with some experiencing fewer side effects and others finding it less effective.
Hair loss can cause psychological distress, but maintaining optimism and self-improvement is crucial. Treatments like minoxidil, finasteride, and potential new options like clascoterone offer hope, though side effects can occur.
Significant hair regrowth was achieved after 4.5 months using 0.5 mg Dutasteride and 5 mg oral Minoxidil. Tips on obtaining prescriptions and discussions on effectiveness and side effects were also shared.
Hair loss was triggered by a testosterone and Masteron cycle, causing scalp tension and shedding. Topical finasteride, RU58841, and oral minoxidil were used to stop shedding and improve scalp condition.
Minoxidil and finasteride work through different mechanisms; minoxidil-dependent hair requires continued use to maintain growth, while finasteride prevents further hair loss but cannot sustain minoxidil gains alone. Current treatments like minoxidil, finasteride, and others need indefinite use, as no permanent solution exists yet.
Androgenic alopecia (AGA) might have evolved to reduce prostate cancer risk by increasing UV exposure to the scalp, but this theory is debated. Treatments like minoxidil and finasteride are used for AGA, though the exact causes and evolutionary reasons for hair loss are unclear.
Dutasteride can stabilize or improve hair loss but may cause side effects like depression and anxiety. Users often switch from finasteride to dutasteride for stronger results, with varied experiences in shedding and regrowth.
A 19-year-old discusses feelings of envy towards men with full heads of hair, sharing their experience with hair loss since age 16. They have been using oral minoxidil and topical finasteride for two years, with initial improvement but continued shedding, and are considering switching to dutasteride.
GT20029 showed promising results for hair growth in a Phase II trial, with the 1.0% twice-weekly regimen being the most effective. Some users expressed skepticism and humor about the product's effects and market availability.
Breezula offers modest hair growth similar to finasteride and is expected to be available by late 2026. It is a safe alternative without hormonal side effects and works well with minoxidil.
The user is taking 2.5 mg dutasteride and 5% minoxidil but is not seeing hair regrowth, and is considering adding RU58841. They are experiencing fatigue and low MCV/MCH, possibly related to dutasteride, and are advised to be patient, consider microneedling, and check for iron deficiency.